Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma.

ABSTRACT:

Purpose

When brain cancer relapses, treatment options are scarce. The use of molecularly matched targeted therapies may provide a feasible and efficacious way to treat individual patients based on the molecular tumor profile. Since little information is available on this strategy in neuro-oncology, we retrospectively analyzed the clinical course of 41 patients who underwent advanced molecular testing at disease relapse.

Methods

We performed Sanger sequencing, targeted next generation sequencing, and immunohistochemistry for analysis of potential targets, including programmed death ligand 1, cyclin D1, phosphorylated mechanistic target of rapamycin, telomerase reverse transcriptase promoter mutation, cyclin-dependent kinase inhibitor 2A/B deletion, or BRAF-V600E mutation. In

SUBMITTER: Lazaridis L 

PROVIDER: S-EPMC10314879 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature